Search

배경: Roseomonas species are slow-growing Gram-negative cocobacillus, and were first reported in 1993. Roseomonas have been isolated from environmental sources and can cause bacteremia in humans, especially in immunocompromised patients. Since these species were difficult to isolate and infections are not common, there are only a few studies on their characteristics. Therefore, we aim to expand our knowledge of clinical features, antimicrobial susceptibility patterns, and treatment outcomes for Roseomonas infections. 방법: From January 2006 to May 2022, patients with Roseomonas isolated from blood and other sources were extracted from three tertiary hospitals in South Korea. Underlying conditions, clinical manifestations, antimicrobial susceptibility patterns, and outcomes were reviewed through the medical records. 결과: During the study period, a total of 51 patients(54.9% were male) were included. The median age was 53 (interquartile range, 33.5-64) years old. Of the 51 patients, 18 patients (35.3%) had malignancies, 6 patients (11.8%) had neutropenia with an absolute neutrophil count of fewer than 1000 cells/mm3, Blood isolates were the most common (37cases), followed by soft tissue (5 cases). 28 cases (55.0%) were cultured after 48 hours of incubation. 41 patients (80.4%) were symptomatic, with fever (35.3%) being the most common symptom. Amikacin showed a high susceptible rate (95.8%) to isolated Roseomonas. Tigecycline and levofloxacin also showed high susceptible rates (93.3% and 86.2%, respectively). On the other hand, piperacillin-tazobactam showed low susceptible rate(5.9%). There were three cases (5.9%) of in-hospital mortality. 결론: Although not common, Roseomonas can cause bacteremia and even death, especially in immunocompromised individuals. Since Roseomonas are challenging to isolate and generally show resistance to antibiotics commonly used for Gram-negative bacterial infections, careful attention is warranted in selecting antibiotics. [ABSTRACT FROM AUTHOR]

배경: Remdesivir is widely used as the antiviral treatment for coronavirus disease 2019 (COVID-19) pneumonia and preventing severe disease. However, due to lack of safety data, remdesivir is not currently recommended for use in patients with an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2. We aim to evaluate the safety of remdesivir use in COVID-19 patients with severe renal impairment. 방법: A single-center, retrospective cohort study was conducted from Jan 2020 to May 2022 at a 2,500-bed tertiary hospital in Seoul, Korea. We reviewed hospitalized COVID-19 patients who received remdesivir with eGFR<30 ml/min/1.73m2 or receiving renal replacement therapy (RRT) at the time of remdesivir use. Baseline demographics, vital signs, clinical characteristics and laboratory findings were reviewed and longitudinal changes up to 28th day after remdesivir use in clinical indexes associated with safety outcome were evaluated. 결과: During the study period, a total of 40 patients (median age 72, 55% male) with severe renal impairment who administered remdesivir were studied. 36 patients (90%) had chronic kidney impairment and 4 (10%) had acute kidney injury. Of the 40 patients, 24 had no history of RRT prior to remdesivir administration (non-dialysis group), and 16 were on dialysis (Hemodialysis group). (Table 1) As a result of repeated measures, eGFR of patients in non-dialysis group showed significant improvement up to 28 days after remdesivir administration. (p=0.009, Figure1) Other laboratory data including white blood cell count, aminotransferases and viral sign as heart rate did not show significant median changes up to 14 days after remdesivir administration in patients with severe renal impairment. (Table 2) 결론: In this cohort of patients with severe renal impairment, remdesivir was not associated with renal or hepatic toxicity. Remdesivir can be considered safely in patients with eGFR<30 ml/min/1.73m2 or receiving RRT. Larger study with comparative group is needed. [ABSTRACT FROM AUTHOR]